Overview

NICE is unable to make a recommendation on ranibizumab (Lucentis) for treating diabetic retinopathy because Novartis did not provide an evidence submission. We will review this decision if the company decides to make a submission.

Guidance development process

How we develop NICE technology appraisal guidance